ストックスクリーナーアプリを入手
20.20
2.96%
0.58
前日終値:
$19.62
開ける：
$19.44
24時間の取引高:
848.25K
Relative Volume:
0.57
時価総額：
$1.60B
収益：
$288.00K
当期純損益:
$-228.06M
株価収益率:
-4.1478
EPS:
-4.87
ネットキャッシュフロー:
$-168.82M
1週間 パフォーマンス:
+0.30%
1か月 パフォーマンス:
-17.35%
6か月 パフォーマンス:
+59.06%
1年 パフォーマンス:
+28.83%
1日の値動き範囲:
$19.44
$20.22
1週間の範囲:
$19.44
$20.86
52週間の値動き範囲:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
VRDN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| VRDN | 20.20 | 1.60B | 288.00K | -228.06M | -168.82M | -4.87 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-14 | 開始されました | BTIG Research | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-05-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-17 | 開始されました | Wells Fargo | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2022-12-19 | 開始されました | Cowen | Outperform |
| 2022-12-19 | 開始されました | Needham | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-12-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-11-18 | 開始されました | SVB Leerink | Outperform |
| 2021-10-12 | 開始されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Viridian Therapeutics Inc (VRDN) 最新ニュース
Principal Financial Group Inc. Buys 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
B. Riley Forecasts Lower Earnings for Viridian Therapeutics - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Viridian Therapeutics (VRDN) Has Captured Investors’ Attention with Recent Breakthroughs - Nasdaq
HC Wainwright Has Bullish Forecast for VRDN FY2024 Earnings - MarketBeat
Viridian Therapeutics’ (VRDN) Buy Rating Reiterated at Needham & Company LLC - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $34.00 - Defense World
FY2024 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for VRDN FY2024 Earnings? - Defense World
(VRDN) Trading Signals - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Should You Sell? - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Viridian Ther - GuruFocus.com
Paradigm Biocapital Advisors LP Increases Stake in Viridian Ther - GuruFocus.com
Wedbush Expects Reduced Earnings for Viridian Therapeutics - MarketBeat
Leerink Partnrs Has Pessimistic View of VRDN FY2024 Earnings - MarketBeat
Lifesci Capital Has Bearish Outlook for VRDN FY2024 Earnings - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.33 - MarketBeat
Viridian Therapeutics Inc (VRDN) Quarterly 10-Q Report - Quartzy
Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics stock target upgraded, keeps buy on veligrotug outlook By Investing.com - Investing.com Canada
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate - Simply Wall St
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses - TipRanks
Viridian Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Viridian Therapeutics earnings missed by $0.09, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Yahoo Finance
Stifel raises Viridian Therapeutics target to $41, keeps buy rating By Investing.com - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighTime to Buy? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Grants 150K Stock Options to New Employees in Retention Push | VRDN Stock News - StockTitan
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Net Present Value Model: Viridian Therapeutics Inc’s Veligrotug - GlobalData
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments
Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat
How To Trade (VRDN) - Stock Traders Daily
VRDN Factor-Based Stock Analysis - Nasdaq
Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
SG Americas Securities LLC Has $374,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics Inc (VRDN) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):